Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Rigel Pharmaceuticals (RIGL) Change in Intangibles (2023 - 2024)

Rigel Pharmaceuticals has reported Change in Intangibles over the past 2 years, most recently at $222000.0 for Q2 2024.

For Q2 2024, Change in Intangibles changed N/A year-over-year to $222000.0; the TTM value through Dec 2024 reached $360000.0, down 97.6%, while the annual FY2024 figure was $360000.0, 97.6% down from the prior year.
Change in Intangibles for Q2 2024 was $222000.0 at Rigel Pharmaceuticals, up from $138000.0 in the prior quarter.
Over five years, Change in Intangibles peaked at $15.0 million in Q1 2023 and troughed at $138000.0 in Q1 2024.